Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’
(20h)
Bausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 fail
(23h)
ARPA-H awards up to $160M to scientists developing custom genetic medicines
(1d)
Chutes & Ladders—Idorsia locks in new CEO after shakeup
(1d)
Roche ends 2 Huntington’s disease programs, including Ionis-partnered tominersen
(1d)
Illumina names new commercial, legal chiefs as sequencing business shows signs of stability
(1d)
Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease
(1d)
GSK cuts losses on $700M upfront Alzheimer’s collab with Alector following 2 clinical failures
(2d)
FDA halts release of new drug rejection letters while working to formalize policy
(2d)
Why biotech revenue projections ‘won’t look as sunny’ once Trump tax bill hits Medicaid enrollment
(2d)
BioPharma Dive
GSK, Hansoh ADC extends survival in lung cancer study
(17h)
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
(20h)
Roche scraps two Ionis-partnered Huntington’s drugs
(1d)
GSK ends brain drug alliance with Alector
(1d)
HHS plan to speed drug research won’t remove ‘self-inflicted’ delays
(1d)
AstraZeneca, Ionis drug fails big heart disease study in major setback
(1d)
AstraZeneca, GSK intensify China ties with Sino Biopharm deals
(2d)
Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
(2d)
Oberland pours up to $400M into MeiraGTx eye gene therapies
(3d)
Kailera says obesity pill succeeds in late-stage trial in China
(3d)
Endpoints News
Apnimed files for IPO as FDA reviews its sleep apnea drug
(11h)
FDA returns to releasing pharma rejection letters with 14 new CRLs
(14h)
FDA rejects Hengrui-Elevar liver cancer drug combo for third time
(15h)
FDA adds 100+ new CDER employees in a quarter for first time since late 2024
(15h)
US biotechs turn secretive as they fear competition from rising Chinese industry
(16h)
German lawmakers pass cost-saving bill that drugmakers say will drive them out
(17h)
Hansoh meets Phase 3 SCLC goal; FDA approves Sanofi on-body injector
(18h)
The data that led Cellular Intelligence to pick up Novo's Parkinson's stem cell therapy
(21h)
Pfizer appoints obesity discovery head; AI startup Xaira makes leadership adjustments
(21h)
ARPA-H bookmarks $160M for custom gene editing treatments. Is it enough?
(1d)
BioSpace
From sequence to scale: Gene editing’s new era in biologics manufacturing
(17h)
AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist
(18h)
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
(18h)
AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space
(20h)
Roche scraps 2 Huntington’s studies, handing Ionis more bad news
(20h)
Amgen continues to defend Tavneos as global regulatory pressure mounts
(1d)
Biopharma R&D needs ‘structural redesign’ to maximize AI impact: report
(1d)
Cancer, rare disease dominate FDA approvals in H1 2026 as AstraZeneca, J&J clean up
(1d)
Psychedelics surge again as Compass, Definium provide more clinical validation
(1d)
Saol boards FDA’s resubmission boat, armed with new survival data
(1d)
STAT News
Nominee for key federal health role has a history of questioning vaccines
(13h)
Roche ends Huntington’s gene-silencing programs
(19h)
We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and more
(19h)
FDA quietly pushes back deadline on electric shock ban
(20h)
How a Boston doctor built a following as a ‘loud and unafraid’ voice in the Trump era
(1d)
New York boys club has a time-tested recipe to protect members’ mental health
(1d)
The primary care crisis paradox
(1d)
Whistleblower takes on health insurance and FDA commissioner candidates
(1d)
Outbreak of diarrhea-causing parasite grows to more than 1,000 cases
(1d)
ARPA-H launches $160 million effort to develop custom gene editing drugs
(1d)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(2w)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(3w)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(1mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(2mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(2mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(3mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(3mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(3mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(3mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(3mo)
Drug Channels
When Access Tightens, Prior Authorization Execution Becomes the Differentiator
(22h)
The Hidden Cost of 340B for Employers and Health Plans
(3d)
The Hidden Cost of 340B for Employers and Health Plans
(3d)
Drug Channels News Roundup, June 2026: PBM Shakeout Accelerates, 340B Enters a New Era, Rebate Questions Persist, Mark Cuban Wins Again, and Ge Bai’s HHS Nomination
(2w)
Drug Channels News Roundup, June 2026: PBM Shakeout Accelerates, 340B Enters a New Era, Rebate Questions Persist, Mark Cuban Wins Again, and Ge Bai’s HHS Nomination
(2w)
BlinkRx Insights: The Questions Manufacturers Wish They Had Asked Before Selecting a Patient Services Partner
(2w)
BlinkRx Insights: The Questions Manufacturers Wish They Had Asked Before Selecting a Patient Services Partner
(2w)
Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains
(2w)
Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains
(2w)
The Digital Front Door to Specialty Therapy May Not Be a Specialty Pharmacy
(3w)
European Biotechnology Magazine
Roche drops two Huntington’s programmes from Ionis
(1d)
AstraZeneca and Ionis miss in key ATTR-CM trial
(1d)
GSK ends Alector neuroscience deal after trial failures
(1d)
Alchemab extends Series A with £25m from British Business Bank
(2d)
AZ buys ex-China rights to Sino’s COPD drug for $2.1bn
(2d)
Boehringer licenses PVT virus platform for cancer vaccines
(3d)
Graph Therapeutics raises $5m to advance I&I pipeline
(3d)
EG 427 rebrands as Cyllene and cashes in €33m Series C
(4d)
Where will AI actually move the needle in drug discovery?
(5d)
Novartis buys UK ADC biotech Myricx Bio in up to $1.5bn deal
(5d)
Drug Hunter
How to “pHLIP” the Script on Drug Delivery
(18h)
ACT-1004-1239
(1d)
TERN-701
(2d)
Getting Large Molecules Into the Brain Through Transferrin Receptor-Mediated Delivery
(3d)
sparsentan
(4d)
avacopan
(1w)
islatravir
(1w)
May 2026 Patent Gazette
(1w)
Boron Neutron Capture Therapy: Precision Radiation With Targeted Delivery
(2w)
Module 5, Section 2: Ligand-Based Design
(2w)
Labiotech.EU
Top biotech deals in June 2026
(19h)
Turning cancer cell dependencies into targeted therapies
(1d)
11 biotech companies leading the way in Denmark
(2d)
The hidden innovation system behind drug repurposing
(3d)
Why Customer Experience Centers are becoming practical infrastructure for life sciences innovation in Europe
(4d)
The biggest biotech funding rounds in June 2026
(4d)
Novartis’ strategy in 2026: rebuilding the pipeline after Entresto
(1w)
The first PROTAC is here. What comes next in protein degradation?
(1w)
Prague: The up-and-coming biotech hub in Central Europe
(1w)
Rethinking precision oncology drug development: AI and tumor biology for smarter therapeutic programs
(2w)
Bio IT World
Signal Management Isn’t Broken; It Simply Belongs to a Previous Era
(1d)
Network Effects: John Quackenbush on How Networks Illuminate Biology Beyond Gene Expression
(2d)
Insilico Medicine Launches Phase III Trial for AI-Developed Drug
(3d)
Digital Brain Twin Tailor-Made for Autism Spectrum Disorder
(4d)
Follow the Money: Inflammatory Bowel Disease Oral Drug, Breast, Colorectal Cancer ADCs, Other Next-Gen, Novel Treatments
(1w)
Anthropic Launches Claude Science, Illumina's Spatial Insights Tool, Wellcome Sanger Institute, Google DeepMind AI Consortium
(1w)
SOPHiA GENETICS, Memorial Sloan Kettering Joint Venture, Illumina Launches Spatial Insights Tool, Wellcome Sanger Institute, Google DeepMind AI Consortium
(2w)
The Spatial Biology Bottleneck: Why AI Models Fail on Complex Tissue & What Actually Fixes It
(2w)
Every Microbiome Tells a Changeable, Computable Story
(2w)
Notes from the Trenches: A Computational Biologist’s View of Drug Discovery’s Digital Revolution
(3w)
GEN News
Macrophage Membrane-Derived Nanoparticles Shows Potential Against Candida Infections
(16h)
Epigenomic Analysis Uncovers New AML Subgroups and Drug Sensitivities
(1d)
Stem Cell Therapy Shows Promise in First Human Parkinson’s Disease Trial
(1d)
Crohn’s Disease Phage Therapy Neutralizes Inflammatory E. coli in Mouse Model
(1d)
Engineered AAVs Harness Glymphatic System to Reach Brain Targets in Mice
(1d)
Ag Genomics Begins to Bear Fruit
(1d)
Top 10 Best-Selling Drugs 2026
(1d)
Virtual Cells Go Multiscale to Predict Complex Biology
(1d)
Advanced Cell Sorting Balances Precision, Scale, and Simplicity
(1d)
Texas Biomed Enters Into a CRADA with U.S. Dept. of War to Help Protect Against Biological Threats
(1d)
Cure Today
A Simple Calf, Hamstring & Low Back Relief Routine for Patients With Cancer
(2d)
What Patients Should Know About Preparing for Cell Therapy
(2d)
Targeted therapy in Lung Cancer Care: What the Research Shows
(2d)
What the 2026 World Cup Teaches About Hope, Resilience, and Recovery
(2d)
Rob Lowe: Clinical Trials Extended My Grandmother's Life
(3d)
A Simple Flexibility Exercise for Patients with Cancer
(3d)
Finding Clarity: Questions and Answers Through Cancer
(3d)
Practical Considerations, Logistical Burdens, and Support Resources for Metastatic EGFR-Positive NSCLC
(3d)
Treatment Landscape of Late-Stage Metastatic EGFR-Positive NSCLC, Side Effect Education, and Shared Decision-Making
(3d)
Nurses Create Food Pantry to Fight Food Insecurity Among Pediatric Cancer Families
(4d)
Contract Pharma
The Friday Brief for July 10, 2026: Companies and Facilities Changing Hands
(18h)
Biohaven Announces Scientific Leadership Changes
(19h)
Takara Bio USA President and CEO Carol Lou to Retire, Succeeded by Andrew Farmer
(1d)
WuXi Biologics Drug Substance Manufacturing Facility Passes FDA Pre-License Inspection
(1d)
Securing Reliable U.S. Supply of Complex Oral Solid Dose Manufacturing
(1d)
From Potential to Practical at DIA 2026: Structure Before AI
(1d)
Olon Completes Major Concord Facility Expansion
(1d)
Gattefossé Accelerates Production Ramp-up at Lufkin Facility
(1d)
Teva and Polpharma Biologics Ink Global Biosimilar Agreement
(1d)
Boehringer Ingelheim, BioMed X Form Eye Health Research Team
(1d)
Pharma Times
Pluripotent stem cell trial for Huntington’s disease
(2d)
Jascayd gains UK licence for treatment of pulmonary fibrosis
(2d)
Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy
(3d)
Compass Pathways reports six‑month data confirming durable profile of COMP360
(3d)
Ferrer and Prilenia begin confirmatory study of pridopidine in Huntington’s disease
(3d)
Wegovy pill launches in UK as first daily oral GLP‑1 for weight management
(5d)
Sofinnova reports Myricx Bio to be acquired by Novartis
(5d)
Francis Crick Institute and Medicines Discovery Catapult open applications for next KQ Labs cohort
(1w)
Novartis receives European Commission approval for Itvisma for spinal muscular atrophy
(1w)
AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project
(1w)
Medcity News
What Is AI Getting Right — and Wrong — in Healthcare’s Revenue Cycle?
(3w)
KFF: Insurer Participation in ACA Marketplaces Is Down
(3w)
FDA Reversal on uniQure Gene Therapy Is Another Sign of Renewed Regulatory Flexibility
(3w)
Combined GI Procedures Are Becoming Routine – AI Can Help Address the Gap in Upper GI Quality Standards
(3w)
The Human Behind the Machine: Why Healthcare Must Resist the Rush To Automate
(3w)
Leveraging Technology to Navigate the New Era of Continuous Organ Distribution
(3w)
InStride Raises $30M to Scale Pediatric Mental Health Support
(3w)
New Cancer Biotech Unveils $27M for Dual-Targeting Prostate Cancer Drug
(3w)
What’s Flowing Beneath the World Cup: How Verily’s Wastewater Monitoring Could Catch the Next Outbreak
(3w)
The FDA’s Bayesian Guidance Could Quietly Reshape Clinical Trial Design
(3w)
Chemical & Engineering News
Memory Lane: Cultivating a right to science education
(12h)
Policy Watch: FDA rejects petition to set PFAS limits in certain foods
(14h)
Chemists get twice the reactivity from a single substitution handle
(16h)
Meet the 2026 CAS Future Leaders
(19h)
What the nose knows
(19h)
C&EN weekly chemistry news quiz, July 10
(22h)
HIV vaccine candidates reach milestone in primates
(1d)
China bets on AI to speed up science despite chip limits
(1d)
ACS Egypt to host Third International Conference on Chemical Sciences
(2d)
80-year-old US Navy asbestos study faces call for retraction
(2d)
The Pharma Letter
Padcev-Keytruda wins broader FDA approval in bladder cancer
(13h)
FDA thumbs up for Sanofi’s subcutaneous Sarclisa Escena
(17h)
Hansoh reports positive Phase III China data for GSK-partnered Ris-Rez in small cell lung cancer
(17h)
Chronic hepatitis C cases set to edge higher across major markets through 2035, says GlobalData
(17h)
NMPA reviews QMS for regulation of vaccine and drug GMP compliance
(18h)
PharmNovo secures capital ahead of Phase II study
(19h)
NICE draft guidance threatens access to Amgen lung cancer drug
(19h)
Russia to postpone "second-extra" rule for vital drugs during public procurements
(20h)
Natco Pharma announces $300 million South Africa expansion
(20h)
Forte’s FB102 achieves statistically-significant improvement in vitiligo
(20h)
Targeted Oncology
FDA Accepts NDA for Varegacestat in Desmoid Tumors
(2d)
Oral CELMoD Golcadomide Advances in Relapsed FL
(2d)
Implementing a Bispecific Antibody Program in Community Oncology—Insights From the American Oncology Network
(2d)
The Evolution of Treatment Goals in Immune Thrombocytopenia
(2d)
After the First TKI Fails: Sequencing Challenges in ROS1-Positive NSCLC
(3d)
Oncologists Consider Treatment Duration and New Options in Progressive Desmoid Tumors
(3d)
Further MonumenTAL-3 Follow-Up Needed for Triplet Regimen in Relapsed Myeloma
(3d)
CMS Proposes Cut to 340B Drug Payments in 2027 Outpatient Rule
(3d)
Adagrasib Plus Cetuximab Falls Short in KRAS G12C–Mutated Colorectal Cancer
(3d)
FDA Rejects Manganese Chloride Tetrahydrate for Liver MRI in Renal Impairment
(3d)
MedWatch
Mikael Dolsten takes chair at AI company BenchSci after withdrawing from Novo Nordisk board race
(19h)
After years of delays: MagCath's female catheter greenlighted for sale in Europe
(20h)
Biotech CEO on new Novo Nordisk partnership: “This could be big”
(20h)
Danish Copli acquired by US company to help pharma firms avoid regulatory violations
(21h)
FDA criticizes Lundbeck: Websites are “false or misleading”
(21h)
Novo Nordisk’s Wimbledon play: Expanding brand beyond weight loss
(22h)
Novo Nordisk’s Wimbledon play: Expanding brand beyond weight loss
(22h)
Leo Pharma takes next step in bringing eczema treatment to children
(23h)
Moderna and the EU sign contract for RSV vaccines
(1d)
China adds Novo's semaglutide to list of critical medicines
(1d)
In The Pipeline
Chemical Onshoring of All Kinds
(1d)
Turning Down the Refinery Heat
(2d)
A Telomerase Inhibitor Revealed
(3d)
Behold the SpudCell
(4d)
Don't Minimize the Side Effects
(1w)
Speaking Up: Who Is, and Who Isn't
(2w)
Antibody-Drug Conjugates: Not Quite Worked Out Yet
(2w)
Here's a Ligand, Go Design a Protein
(2w)
Machine-Learning Mass Spec Data: Hmmm
(3w)
Covid-19 Vaccinations and the Heart
(4w)
Pharmaphorum
Non-profit DNDi preps phase 3 trials for dengue antibody
(21h)
Bausch + Lomb drug fails in glaucoma, but a new use beckons
(22h)
Roche abandons two Huntington's drug candidates
(23h)
Bayer gets €3bn from Apollo for contraceptives unit stake
(1d)
Moderna's mResvia gets shot in the arm from EU contract
(1d)
Keenova eyes Xiaflex as first drug for plantar fibromatosis
(1d)
GSK ends dementia alliance with Alector after setbacks
(1d)
NICE aims to cut funding for Amgen lung cancer drug Lumykras
(2d)
AZ, Ionis hit by unexpected Wainua trial failure
(2d)
UK first in Europe to clear Boehringer's IPF drug Jascayd
(2d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(3w)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(3w)
Webinar: Learn how to accelerate the early stages of drug discovery
(3w)
Therapy enables 89% survival rate in myeloma patients
(3w)
Ulcerative colitis treatment shows best-in-class potential
(3w)
UK patients to benefit from approval of weight loss tablet
(3w)
Vertex presents new data on Casgevy in children
(3w)
DDW Highlights: 16 June 2026
(3w)
LXR inverse agonist shows promise in liver disease
(3w)
Guide: One solution – from R&D, to QC
(3w)
HIT Consultant
Health Payers Have Invested in Modern Data Infrastructure. Access Control Hasn’t Kept Up.
(1d)
The Technology Gap Holding Provider-Sponsored Health Plans Back
(1d)
Grounding Clinical AI in Evidence: The Critical Role of Human Oversight and Continuous Validation
(1d)
Beyond the Screen: How Telepsychiatry Must Evolve in theEra of Interventional Psychiatry
(1d)
Scaling Enterprise Imaging: IT Lessons from Digital Pathology
(1d)
AccurKardia and Wellysis Form Multi-Year Strategic Partnership to Deliver End-to-End Cardiac Monitoring
(1d)
Why Health Tech Leaders Need to Stop Setting Goals and Start Drawing Ladders
(2d)
KLAS Releases Global Hospital EHR Market Share 2026 Report: Purchasing Decisions Hit 5-Year Low
(2d)
IT Teams are the New Drivers of Healthcare Efficiency and Value
(3d)
What Produce Longevity Can Teach Us About Personalized Health Care
(4d)
Insights: Pink Sheet
US FDA Proposes One Registration For Distributed Drug Manufacturing Networks
(10h)
US FDA Hiring Binge: CDER, CBER Report Q3 Bump, First Since Trump Administration Cuts
(12h)
Unpause? US FDA Posts 14 New CRLs After Temporary Halt
(15h)
Pink Sheet Podcast: Complete Response Letter And DTC Ad Regulations, Potential US FDA Reorg
(15h)
Recent And Upcoming US FDA Advisory Committee Meetings
(15h)
EMA Fast-Tracks Daraxonrasib In Test Run For New Phased Review Process
(17h)
‘Excited And Confident:’ PIC/S Builds Momentum For Harmonized E6(R3) Inspections
(17h)
Is There ‘Leeway’ For EU Countries To Extend Wastewater Directive Costs Beyond Pharma And Cosmetics?
(17h)
Japan Awards Global-First Reimbursement To Ishin’s Allostem, Heihe’s Risovalisib
(1d)
National Priority Voucher Critics Ask Why The US FDA Needs Another Expedited Review Pathway
(1d)
BioXconomy
Germany doubles pharma rebates to curb costs
(16h)
Legislative changes alter GTN landscape
(21h)
Sandoz launches direct-to-patient drug platform
(21h)
Leo Cancer Care lands $65m Series D to bring upright proton platform to underserved communities
(23h)
Realizing Integrated Planning and Gross-to-Net
(1d)
Price cuts boosted PCSK9 inhibitor use in Medicare
(1d)
Platforms won’t power the next generation of clinical trials. AI ecosystems will.
(1d)
ACA insurers seek 14% hike for 2027 coverage
(1d)
High prior authorization rates drive MA exodus
(1d)
Regeneron to provide gene therapy for genetic hearing loss for free
(1d)
BioCentury
With first clinical data due next year, Scribe to test IPO market: Finance Report
(8h)
FDA resumes CRL releases, citing ‘commitment to transparency’
(8h)
Perspective — siRNAs are better than ASOs
(9h)
2Q26 Wrap: Income inequality
(9h)
Can M&A momentum carry biotech through year-end?
(10h)
Roivant’s Gline: From spin-cos to commercial conviction
(1d)
New CEO appointments include Idorsia, Arrakis leaders
(1d)
Science Spotlight: Actionable pathways for cachexia and radioresistance in lung cancer
(1d)
Ionis’ ATTR-CM miss: Were overlapping mechanisms or the modality to blame?
(1d)
Biotech in Burnham’s Britain
(1d)
SCRIP
Gilead’s Biggest Buys Balance Drug Candidate Needs With Platform Desires
(11h)
Roche Pulls Plug On Two Antisense Oligonucleotide Programs In Huntington’s
(11h)
Pharma At The Midyear: Taking Stock Of Financial Forecasts
(12h)
LEO Reports Phase II Pediatric Data As Tralokinumab Advances Through Phase III
(17h)
Bayer Break-Up Rumors Revived After €3bn Apollo Pact
(19h)
Executives On The Move: Eight CEOs And Three CFOs Among This Week’s Changes
(20h)
Global Phase III Trial For Serum Institute/Visterra’s Dengue Candidate Sharing Voyxact Platform
(23h)
Mega-Round Surge Leads Big Q2 Venture Funding Boom
(1d)
InxMed’s Ifebemtinib Moves Ahead Amid Positive Phase II NSCLC Combo Data
(1d)
Tarsus Will Move Into Chronic Retinal Disease With iRenix Takeout
(1d)